Literature DB >> 21907905

The use of GPCR structures in drug design.

Miles Congreve1, Christopher Langmead, Fiona H Marshall.   

Abstract

Structure-based drug discovery is routinely applied to soluble targets such as proteases and kinases. It is only recently that multiple high-resolution X-ray structures of G protein-coupled receptors (GPCRs) have become available. Here we review the technology developments that have led to the recent plethora of GPCR structures. These include developments in protein expression and purification as well as techniques to stabilize receptors and crystallize them. We discuss the findings derived from the new structures with regard to understanding GPCR function and pharmacology. Finally, we examine the utility of structure-based drug discovery approaches including homology modeling, virtual screening, and fragment screening for GPCRs in the context of what has been learnt from other target classes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907905     DOI: 10.1016/B978-0-12-385952-5.00011-7

Source DB:  PubMed          Journal:  Adv Pharmacol        ISSN: 1054-3589


  16 in total

1.  Structure of class B GPCR corticotropin-releasing factor receptor 1.

Authors:  Kaspar Hollenstein; James Kean; Andrea Bortolato; Robert K Y Cheng; Andrew S Doré; Ali Jazayeri; Robert M Cooke; Malcolm Weir; Fiona H Marshall
Journal:  Nature       Date:  2013-07-17       Impact factor: 49.962

Review 2.  The GPCR Network: a large-scale collaboration to determine human GPCR structure and function.

Authors:  Raymond C Stevens; Vadim Cherezov; Vsevolod Katritch; Ruben Abagyan; Peter Kuhn; Hugh Rosen; Kurt Wüthrich
Journal:  Nat Rev Drug Discov       Date:  2012-12-14       Impact factor: 84.694

3.  High-throughput identification and characterization of novel, species-selective GPR35 agonists.

Authors:  Zaynab Neetoo-Isseljee; Amanda E MacKenzie; Craig Southern; Jeff Jerman; Edward G McIver; Nicholas Harries; Debra L Taylor; Graeme Milligan
Journal:  J Pharmacol Exp Ther       Date:  2012-12-21       Impact factor: 4.030

Review 4.  Structure of Class B GPCRs: new horizons for drug discovery.

Authors:  Andrea Bortolato; Andrew S Doré; Kaspar Hollenstein; Benjamin G Tehan; Jonathan S Mason; Fiona H Marshall
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 5.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Authors:  Louis M Luttrell
Journal:  Mol Endocrinol       Date:  2014-01-16

Review 6.  Insights into the structure of class B GPCRs.

Authors:  Kaspar Hollenstein; Chris de Graaf; Andrea Bortolato; Ming-Wei Wang; Fiona H Marshall; Raymond C Stevens
Journal:  Trends Pharmacol Sci       Date:  2013-12-18       Impact factor: 14.819

Review 7.  Structure-based drug screening for G-protein-coupled receptors.

Authors:  Brian K Shoichet; Brian K Kobilka
Journal:  Trends Pharmacol Sci       Date:  2012-04-13       Impact factor: 14.819

8.  SLC Transporters: Structure, Function, and Drug Discovery.

Authors:  Claire Colas; Peter Man-Un Ung; Avner Schlessinger
Journal:  Medchemcomm       Date:  2016-03-28       Impact factor: 3.597

9.  Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs.

Authors:  Brian D Hudson; Elisabeth Christiansen; Irina G Tikhonova; Manuel Grundmann; Evi Kostenis; David R Adams; Trond Ulven; Graeme Milligan
Journal:  FASEB J       Date:  2012-08-23       Impact factor: 5.191

10.  Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3.

Authors:  Brian D Hudson; Irina G Tikhonova; Sunil K Pandey; Trond Ulven; Graeme Milligan
Journal:  J Biol Chem       Date:  2012-10-12       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.